Benzinga
16 May 2026, 18:47 UTC · 26w ago
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Impact · against what's priced in
CADL is likely to see a positive price reaction as the reporting of a 39% improvement in disease-free survival in a pivotal Phase 3 trial provides a concrete catalyst for regulatory approval. While technical indicators suggest the stock is overbought, the fundamental strength of the clinical data typically outweighs short-term RSI concerns for clinical-stage biotechs.
- CADL+0.80
No priced-in read yet
- In context
The report of a 39% improvement in disease-free survival in a pivotal Phase 3 trial for localized prostate cancer is a major value-driving event that significantly increases the likelihood of drug approval.
Read from the article alone

Search tags




